Therefore, intrahepatic and extracellular HMGB1 play distinct roles, and blocking the HMGB1-NF-κB axis and HMGB1 translocation may serve as a potential therapeutic target for reducing inflammation and NAFLD. Here, HMGB1 is linked to metabolic dysfunction-associated steatotic liver disease.